NCT07822919
A Study of AWT020 in Participants With Advanced Solid Tumors
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 4 versions: 4 with changes below.
- Minor Start date changed from estimate of Sep 11, 2026 to Oct 15, 2026
- Study sites: 2 to 3
- Minor Study sites: 1 to 2
- Notable Recruitment opened
- Site details revised
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Adverse Events (AEs) [Safety]
Timeframe: Throughout the study up to 30 months
Serious Adverse Events (SAEs) [Safety]
Timeframe: Throughout the study up to 30 months
Treatment-emergent Adverse Events (TEAEs) [Safety]
Timeframe: Throughout the study up to 30 months
Adverse Events of Special Interest (AESIs) [Safety]
Timeframe: Throughout the study up to 30 months
Dose-limiting Toxicities (DLTs) [Tolerability]
Timeframe: Throughout the study up to 30 months
Secondary (16)
Maximum Observed Serum Concentration (Cmax)
Time to Cmax (Tmax)
Area Under the Curve (AUC)
Clearance (CL)
Volume of Distribution (Vss)
Show 11 moreShow less
Half-life (t1/2)
Overall Response Rate (ORR)
Disease Control Rate (DCR)
Progression-free Survival (PFS)
Immune-related ORR (iORR)
Immune-related DCR (iDCR)
Immune-related PFS (iPFS)
Immune-related TTR (iTTR)
Immune-related DOR (iDOR)
Overall Survival
Immunogenicity of AWT020
Arms and interventions
AWT020Experimental
Participants receiving intravenous infusion of AWT020
Biologicals: AWT020
Sites
3 sites in 1 country